Volume 27, No 1, Jan 2017

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 27 Issue 1, January 2017: 147-150   |  Open Access

LETTERS TO THE EDITOR

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

Zhenkun Na¹, Siok Ping Yeo², Sakshibeedu R Bharath¹, Matthew W Bowler^4,5, Esra Balıkçı¹, Cheng-I Wang² and Haiwei Song^1,3

¹Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673, Singapore
²Singapore Immunology Network, 8a Biomedical Grove, Singapore 138648, Singapore
³Department of Biochemistry, National University of Singapore, 14 Science Drive, Singapore 117543, Singapore
⁴European Molecular Biology Laboratory, Grenoble Outstation, 71 avenue des Martyrs, CS 90181 F-38042 Grenoble, France
⁵Unit of Virus Host-Cell Interactions, Univ. Grenoble Alpes-EMBL-CNRS, 71 avenue des Martyrs, CS 90181 F-38042 Grenoble, France Correspondence: Haiwei Song, Tel: +65 65869700 E-mail: haiwei@imcb.a-star.edu.sg; Cheng-I Wang, Tel: +65 64070083(Wang_ChengI@immuno.a-star.edu.sg)

PD-1 is a type I immune inhibitory transmembrane receptor of the CD28 family that modulates the activity of T cells in peripheral tissues1. It is expressed in T cells, B cells, monocytes, natural killer cells and many tumor-infiltrating lymphocytes2. Binding of PD-1 to its ligands PD-L1 and PD-L2 reduces T-cell activity3.

10.1038/cr.2016.77

FULL TEXT | PDF

Browse 2783